NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 70 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Adoptive Cell Therapy;
Cell Therapy;
Gene Therapy

Recruitment Keyword(s)



Non-Small Cell Lung Cancer;
Breast Cancer;
Gastrointestinal/Genitourinary Cancers;
Ovarian Cancer

Investigational Drug(s)

Sleeping Beauty Transposed PBL

Investigational Device(s)



Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Aldesleukin
Biological/Vaccine: Sleeping Beauty Transposed PBL

Supporting Site

National Cancer Institute


A person s white blood cells can be modified in a lab to recognize certain changes in their tumor. Many of these cells are collected from the person, modified, then given back to the person. This may help treat some cancers.


To learn if a person s white blood cells modified with T-cell receptors can cause solid tumors to shrink.


People ages 18-70 who have cancer of the gastrointestinal tract, genitourinary tract, ovary, breast, or lung that has spread, or who have glioblastoma.


Participants will be screened and have their cells prepared for treatment in another protocol.

Participants will be hospitalized one week before treatment. They will stay approximately 3 - 4 weeks after treatment.

Participants will get the modified white blood cells and chemotherapy through an IV catheter, which is a small plastic tube inserted in a vein.

Participants will take drugs by mouth to prevent infection. They will receive filgrastim as a shot or injection under the skin.

Participants will have tests before, during, and after treatment:

Heart, blood, and urine tests

Chest X-ray

Physical exam

Scans: They will lie in a machine that takes pictures of the body.

Possible apheresis: The participant s blood is removed through a needle in an arm. The blood goes through a machine that removes the white blood cells. The rest of the blood is returned through a needle in the other arm.

Participants will have visits about 6 and 12 weeks after treatment. If they are responding to treatment, they will then have visits every 3-6 months for 3 years. Then they will join another study and be followed about 12 more years.

--Back to Top--



-Patients with histologically confirmed solid cancer that falls into one of four cohorts:

--Gastrointestinal and genitourinary (Cohort 1),

--Breast and ovarian (Cohort 2),

--Non-small cell lung cancer (NSCLC), NSCLC includes but is not limited to squamous cell carcinoma, adenosquamous carcinoma or adenocarcinomas (Cohort 3),

--Glioblastoma (Cohort 4)

-Patients must have evaluable or measurable disease per RECIST 1.1 with at least one lesion that is resectable for TIL generation with minimal morbidity plus at least one other lesion that can be measured. Metastatic disease is required for Cohorts 1-3 but is not required for Cohort 4.

-Patients must have:

--previously received standard systemic therapy for their advanced cancer and have been either non-responders or have recurred, specifically:

---Patients with metastatic colorectal cancer must have received oxaliplatin or irinotecan (or similar agents)

---Patients with breast and ovarian cancer must be refractory to first-line treatments

---Patients with lung cancer must have received at least one platinum-based chemotherapy regimen and at least one FDA-approved targeted treatment (when appropriate)

---Patients with glioblastoma must have progression of disease after radiotherapy (including patients that undergo surgery for recurrent disease and are rendered NED). This includes recurrent GBM after receiving all standard first-line treatment, including surgery (if feasible due to neurosurgical and neuro- anatomical considerations) and adjuvant radiotherapy +/- chemotherapy. OR

--declined standard treatment

-For Cohorts 1-3: Patients with 3 or fewer brain metastases that are < 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.

-For Cohort 3: Patients must have documented FEV1 > 60% predicted.

-Age greater than or equal to 18 years and less than or equal to 70 years.

-For Cohorts 1-3: Clinical performance status of ECOG 0 or 1.

-For Cohort 4: Patients must have Karnofsky performance status of greater than or equal to 60.

-The effects of study treatment on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) at time of study entry, for the duration of treatment and up to 4 months after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.


--Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)

--Seronegative for active hepatitis B, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.


--ANC > 1,000/mm^3 without the support of filgrastim

--WBC greater than or equal to 3,000/mm^3

--Platelet count greater than or equal to 100,000/mm^3

--Hemoglobin > 8.0 g/dL. Subjects may be transfused to reach this cut-off.


--Serum ALTlAST less than or equal to 5.0 x ULN

--Serum creatinine less than or equal to 1.6 mgldL

--Total bilirubin less than or equal to 1.5 mg/dL, except in patients with Gilbert s Syndrome, who must have a total bilirubin < 3.0 mg/dL.

-More than four weeks must have elapsed since completion of any prior systemic therapy and enrollment.

Note: Patients may have undergone minor surgical procedures or limited field radiotherapy (with the exception of patients with glioblastoma) within the four weeks before enrollment, as long as any related major organ toxicities have recovered to less than or equal to grade 1.

-For Cohort 3: More than two weeks must have elapsed since any prior palliation for major bronchial occlusion or bleeding and enrollment, and patient s toxicities must have recovered to less than or equal to grade 1.

-For Cohort 4: Patients must be at least four weeks from radiation therapy. Additionally, patients must be at least six weeks from nitrosoureas, four weeks from temozolomide, three weeks from procarbazine, two weeks from vincristine and four weeks from last bevacizumab administration. Patients must be at least four weeks from other cytotoxic therapies not listed above and two weeks for non-cytotoxic agents (e.g., interferon) including investigative agents. Patient s toxicities must have recovered to less than or equal to grade 1.

-Ability of subject to understand and the willingness to sign a written informed consent document.

-Willing to sign a durable power of attorney.

-Subjects must be co-enrolled on protocol 03-C-0277.


-Pregnant women are excluded from this study because study treatment s potential for teratogenic or abortifacient effects is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with study therapy, breastfeeding should be discontinued if the mother is treated on this trial.

-Concurrent systemic steroid therapy, except for patients with glioblastoma (Cohort 4).

-Active systemic infections requiring anti-infective treatment, coagulation disorders or any other active or uncompensated major medical illnesses.

-For Cohort 3: Any major bronchial occlusion or bleeding not amenable to palliation.

-For Cohort 4: Clinically significant hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding six months that were not related to glioma surgery.

Note: History of prior intratumoral bleeding is not an exclusion criterion; however, patients with a history of prior intratumoral bleeding will need to undergo a non- contrast head CT to exclude acute bleeding.

-Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).

-Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune- competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)

-History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.

-History of coronary revascularization or ischemic symptoms.

- Documented LVEF less than or equal to 45% tested in patients:

--Age greater than or equal to 65 years

--With clinically significant atrial and/or ventricular arrhythmias, including but not limited to: atrial fibrillation, ventricular tachycardia, second- or third-degree heart block, or have a history of ischemic heart disease and/or chest pain.

-Documented FEVl less than or equal to 50% predicted tested in patients with:

--A prolonged history of cigarette smoking (greater than or equal to 20 pack-year smoking history within the past two years).

--Symptoms of respiratory dysfunction.

-Clinically significant patient history which in the judgment of the Principal Investigator (PI) would compromise the patients ability to tolerate high-dose aldesleukin.

-Patients who are receiving any other investigational agents.

--Back to Top--


Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ. Bispecific T-cells expressing polyclonal repertoire of endogenous >= T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther. 2013 Mar;21(3):638-47. doi: 10.1038/mt.2012.267. Epub 2013 Jan 8.

Ivics Z, Hackett PB, Plasterk RH, Izsv(SqrRoot)(Degree)k Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997 Nov 14;91(4):501-10.

Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013 Feb;36(2):112-23. doi: 10.1097/CJI.0b013e3182811ce9.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Steven A. Rosenberg, M.D.
National Cancer Institute (NCI)

NCI/Surgery Branch Recruitment Center
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 2-1730
10 Center Drive
Bethesda, Maryland 20892
(866) 820-4505

Recruitment Center - SB
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Building 10, Room 2-1730, Bethesda, Maryland 20892, United States
(866) 820-4505

Clinical Trials Number:


--Back to Top--